Comparison of MRD assessments by BM vs PB MS
| . | BM aspirate for MRD . | PB for MS MRD . |
|---|---|---|
| Advantages | Well established, standardized, and validated | Not invasive Patient preference Allows for more frequent and dynamic monitoring |
| Disadvantages | Invasive, limited by patient tolerability Hemodilution may affect sensitivity Cannot assess for extramedullary disease Limited by patchy BM involvement | Half-life of IgG (∼23 days) and IgA (4-7 days) may lead to false “positive” MRD assessment; half-life even longer with smaller concentrations Not useful in nonsecretory disease For clonotypic MS, requires a baseline sample to enable tracking |
| . | BM aspirate for MRD . | PB for MS MRD . |
|---|---|---|
| Advantages | Well established, standardized, and validated | Not invasive Patient preference Allows for more frequent and dynamic monitoring |
| Disadvantages | Invasive, limited by patient tolerability Hemodilution may affect sensitivity Cannot assess for extramedullary disease Limited by patchy BM involvement | Half-life of IgG (∼23 days) and IgA (4-7 days) may lead to false “positive” MRD assessment; half-life even longer with smaller concentrations Not useful in nonsecretory disease For clonotypic MS, requires a baseline sample to enable tracking |